Blagojche Gjorgjioski

Mr. Blagojche Gjorgjioski

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MSMonika Simjanoska
Monika Simjanoska
DSDragan Shahpaski
Dragan Shahpaski
JDJovana Dobreva
Jovana Dobreva
DBDjansel Bukovec
Djansel Bukovec
BGBlagojche Gjorgjioski
Blagojche Gjorgjioski
MATJAZ GAMSMATJAZ GAMS
MATJAZ GAMS
The integration of artificial intelligence (AI) into clinical workflows is advancing even before full compliance with the European Union Cross-Border eHealth Network (MyHealth@EU) framework is achieved. While AI-based clinical decision support systems are automatically classified as high risk under the European Union’s AI Act, cross-border health data exchange must also satisfy MyHealth@EU interoperability requirements. This creates a dual-compliance challenge: vertical safety and ethics controls mandated by the AI Act and horizontal semantic transport requirements enforced through Open National Contact Point (OpenNCP) gateways, many of which are still maturing toward production readiness. This paper provides a practical, phase-oriented tutorial that enables developers and providers to embed AI Act safeguards before approaching MyHealth@EU interoperability tests. The goal is to show how AI-specific metadata can be included in the Health Level Seven International Clinical Document Architecture and Fast Healthcare Interoperability Resources messages without disrupting standard structures, ensuring both compliance and trustworthiness in AI-assisted clinical decisions. We systematically analyzed Regulation (EU) 2024/1689 (AI Act) and the OpenNCP technical specifications, extracting a harmonized set of overlapping obligations. The AI Act provisions on transparency, provenance, and robustness are mapped directly onto MyHealth@EU workflows, identifying the points where outgoing messages must record AI involvement, log provenance, and trigger validation. To operationalize this mapping, we propose a minimal extension set, covering AI contribution status, rationale, risk classification, and Annex IV documentation links, together with a phase-based compliance checklist that aligns AI Act controls with MyHealth@EU conformance steps. A simulated International Patient Summary transmission demonstrates how Clinical Document Architecture/Fast Healthcare Interoperability Resources extensions can annotate AI involvement, how OpenNCP processes such enriched payloads, and how clinicians in another member state view the result with backward compatibility preserved. We expand on security considerations (eg, Open Worldwide Application Security Project generative AI risks such as prompt injection and adversarial inputs), continuous postmarket risk assessment, monitoring, and alignment with MyHealth@EU’s incident aggregation system. Limitations reflect the immaturity of current infrastructures and regulations, with real-world validation pending the rollout of key dependencies. AI-enabled clinical software succeeds only when AI Act safeguards and MyHealth@EU interoperability rules are engineered together from day 0 . This tutorial provides developers with a forward-looking blueprint that reduces duplication of effort, streamlines conformance testing, and embeds compliance early. While the concept is still in its early phases of practice, it represents a necessary and worthwhile direction for ensuring that future AI-enabled clinical systems can meet both European Union regulatory requirements from day 1. risks such as prompt injection and adversarial inputs), continuous postmarket risk assessment, monitoring, and alignment with MyHealth@EU’s incident aggregation system. Limitations reflect the immaturity of current infrastructures and regulations, with real-world validation pending the rollout of key dependencies.

14 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDjansel Bukovec
Djansel Bukovec
BGBlagojche Gjorgjioski
Blagojche Gjorgjioski
MMMonika Simjanoska Misheva
Monika Simjanoska Misheva
GKGoran Kungulovski
Goran Kungulovski
Background: Tumors exhibit substantial cellular and molecular diversity driven by genetic and epigenetic mechanisms. Large-scale profiling efforts have established aberrant DNA methylation as a universal hallmark of cancer. Beyond changes in mean methylation levels, tumor tissues exhibit elevated DNA methylation variability at specific genomic regions within and across tumors. This constitutes a fundamental dimension of cancer epigenomes, reflecting disrupted maintenance of epigenomic states and stochastic drift, which may enable adaptation to the microenvironment, phenotypic plasticity, invasion, disease progression, and treatment resistance. However, the genome-wide organization and functional consequences of DNA methylation variability across cancer types remain incompletely understood. Methods: We analyzed paired tumor–normal DNA methylation profiles across 16 cancer types to systematically quantify DNA methylation variability. Pan-cancer DNA methylation variability was consistently observed using complementary statistical approaches and multiple modes of data representation. We identified cancer-specific and pan-cancer differentially variable regions and evaluated their associations with genomic features, transcriptional and chromatin regulators, and biological processes. Variability was quantified using three measures per sample: the proportion of intermediately methylated sites (PIM), genome-wide Shannon entropy, and a DNA methylation–based stemness index. Associations with genomic instability, tumor biological features, and clinical outcomes were subsequently assessed. Results: Tumor samples consistently exhibited higher DNA methylation variability than matched normal tissues, reflected by increased dispersion and wider interquartile ranges. Pan-cancer variably methylated regions were depleted in promoters and enriched in open sea regions, in heterochromatic H3K27me3-decorated PRC2-repressed domains, and at enhancers. They preferentially contained motifs for transcription factors involved in developmental regulation. Elevated DNA methylation variability, captured by higher PIM, entropy, and stemness scores, was associated with increased genomic instability manifested by higher aneuploidy, increased DNA break points, a greater fraction of the genome altered, and increased tumor mutational burden, as well as with aggressive tumor features such as lymph node involvement, post-therapy neoplasm events, and elevated hypoxia scores. Importantly, tumors with high DNA methylation variability exhibited significantly worse overall, progression-free, and disease-free survival. Conclusions: DNA methylation variability is a pervasive and clinically relevant feature of tumor epigenomes, reflecting epigenetic and genetic instability, expanded regulatory plasticity, and tumor aggressiveness.

2 August 2026 in Future Internet
Verified
Journal Article
Open access
PDF file
BGBlagojche Gjorgjioski
Blagojche Gjorgjioski
DBDjansel Bukovec
Djansel Bukovec
IVIvana Vichentijevikj
Ivana Vichentijevikj
IKIvan Kitanovski
Ivan Kitanovski
KMKostadin Mishev
Kostadin Mishev
MSMonika Simjanoska
Monika Simjanoska
The emergence of Large Language Models (LLMs) has significantly advanced computational biology, yet their integration into autonomous, multi-agent systems (MASs) and clinical workflows remains challenging due to systemic architectural fragmentation. To quantify the operational readiness and regulatory compliance of bioinformatics LLMs, we developed the Multi-Agent Readiness Score (MARS), a standardized evaluation framework assessing models across four structural dimensions: Governance & Accessibility, Biological Competence, Technical Maturity, and Agentic Orchestration. The framework incorporates compliance criteria from the EU AI Act, HL7 FHIR, HL7 CDA, and MyHealth@EU standards. To empirically validate this domain-agnostic methodology, we applied it to a highly mature subset of the field: a diverse cohort of 43 prominent genomic LLMs. Our assessment revealed a severe, industry-wide readiness gap: the majority of models fell into “Not Suitable” or “Research Prototype” tiers, lacking essential technical interfaces, structured communication schemas, and provenance tracking. Furthermore, the data demonstrated a ’competence-readiness gap’, where models scale in biological predictive competence without corresponding improvements in engineering utility. The primary barrier to scalable bioinformatics AI is no longer biological competence, but operational and architectural incompatibility. By quantifying integration friction, MARS provides a crucial, reproducible metric to audit model maturity, guide system architecture, and ensure future models are structurally prepared for the rigorous regulatory demands of precision medicine workflows.

24 July 2025 in JMIR Preprints
Verified
Preprint
Open access
MSMonika Simjanoska
Monika Simjanoska
DSDragan Shahpaski
Dragan Shahpaski
JDJovana Dobreva
Jovana Dobreva
DBDjansel Bukovec
Djansel Bukovec
BGBlagojche Gjorgjioski
Blagojche Gjorgjioski
MATJAZ GAMSMATJAZ GAMS
MATJAZ GAMS
BACKGROUND The integration of AI within clinical workflows is anticipated even prior to achieving full compliance with the MyHealth@EU framework. Myriad use cases have been presented internationally and garnered media attention. AI-based Clinical Decision Support Systems (CDSS) are automatically classified as high-risk under the EU AI Act, while cross-border data sharing in Europe must satisfy the MyHealth@EU interoperability rules. Development teams will inevitably face a dual-compliance challenge: vertical safety and ethics controls mandated by the AI Act, and horizontal semantic-transport requirements enforced through OpenNCP software’s gateways; some of which are yet to be brought to production readiness. OBJECTIVE The aim of the paper is to provide a practical, phase-oriented tutorial that enables developers and providers to embed AI Act controls prior to approaching the MyHealth@EU interoperability tests. The goal is to enable the inclusion of AI-specific tags in the HL7 CDA and HL7 FHIR messages without compromising the standard structure, while ensuring trustworthiness in the AI-aided clinical decision. METHODS We systematically analysed Regulation (EU) 2024/1689 (henceforth “AI Act”) and the MyHealth@EU/OpenNCP technical specifications, cross-referencing official guidance and semantic assets to extract a harmonised set of overlapping compliance obligations. RESULTS The mandated duties within the AI Act’s transparency, provenance, and robustness provisions are precisely overlaid onto the existing MyHealth@EU workflow. These define where any outgoing clinical message must record AI involvement, log the provenance of this involvement, and trigger validation of the information. A lean extension set adds AI contribution status, rationale, risk class, and an Annex IV (AI Act) link while remaining schema compliant. A phase-based checklist then threads every high-risk AI control giving developers one path to simultaneous AI-Act and MyHealth@EU alignment. CONCLUSIONS AI-enabled clinical software succeeds only when AI Act safeguards and MyHealth@EU interoperability rules are engineered together from ‘day zero’. The proposed checklist and lightweight CDA/FHIR extensions let developers embed, test, and prove high-risk AI compliance while injecting the necessary AI metadata directly into standard messages. This integrated blueprint cuts duplication of effort and delivers clinically trustworthy, AI-annotated reports that flow safely and instantly across national borders. CLINICALTRIAL N/A